Close Menu

NEW YORK – Interpace Biosciences reported before the open of the market Tuesday that its second quarter revenues fell 14 percent year over year.

For the three months ended June 30, the Parsippany, New Jersey-based cancer diagnostics firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.